Strong new comparative data for Refixia in hemophilia B

Adults with hemophilia B who received a single dose Refixia (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein).

The head-to-head paradigm7 trial also observed a longer half-life for Refixia, from Danish diabetes care giant Novo Nordisk (NOV: N). These pharmacokinetic findings were presented today at the WFH 2018 World Congress in Glasgow, UK.

The trial showed that the total factor IX exposure of Refixia in patient plasma after injection of a single dose (50 IU/kg) was 4.39-fold greater than for rFIXFc, as measured by the area under the curve (AUC). Seven days after injection, the factor IX activity in patients treated with a single dose of Refixia was six-fold greater than that of patients treated with rFIXFc at the same dose.